NovoCure

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

CEO

Frank Leonard

CEOFrank Leonard

Employees

1,488

Employees1,488

Headquarters

St. Helier, Jersey

HeadquartersSt. Helier, Jersey

Founded

2000

Founded2000

Employees

1,488

Employees1,488

NVCR Key Statistics

Market cap

1.13B

Market cap1.13B

Price-Earnings ratio

-6.29

Price-Earnings ratio-6.29

Dividend yield

—

Dividend yield—

Average volume

1.66M

Average volume1.66M

High today

$10.37

High today$10.37

Low today

$9.93

Low today$9.93

Open price

$10.12

Open price$10.12

Volume

1.85M

Volume1.85M

52 Week high

$23.18

52 Week high$23.18

52 Week low

$9.82

52 Week low$9.82

Stock Snapshot

The current NovoCure(NVCR) stock price is $10.14, with a market capitalization of 1.13B. The stock trades at a price-to-earnings (P/E) ratio of -6.29.

As of 2026-02-08, NovoCure(NVCR) stock has fluctuated between $9.93 and $10.37. The current price stands at $10.14, placing the stock +2.1% above today's low and -2.2% off the high.

The NovoCure(NVCR)'s current trading volume is 1.85M, compared to an average daily volume of 1.66M.

During the past year, NovoCure(NVCR) stock moved between $9.82 at its lowest and $23.18 at its peak.

NVCR News

Simply Wall St 5h

Assessing NovoCure Valuation After Prolonged Share Price Weakness In Tumor Treating Fields Story

NovoCure (NVCR) has drawn attention after a prolonged share price slump, with negative returns over the past year and the past 3 months prompting investors to r...

TipRanks 3d

Maintaining Buy on NovoCure: Viewing CMS Billing Revocation as a Temporary Administrative Setback with Limited Long-Term Impact

NovoCure, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the...

Seeking Alpha 3d

NovoCure projects $13M monthly revenue hit as Medicare revokes billing privileges

NovoCure (NVCR) shares lost ~2% on Thursday after the oncology-focused MedTech projected roughly a $13M monthly revenue impact following a decision by the Cente...

Analyst ratings

71%

of 7 ratings

Buy

71.4%

Hold

28.6%

Sell

More NVCR News

TipRanks 3d

NovoCure Faces CMS Billing Revocation, Revenue Impact Uncertain

NovoCure ( (NVCR) ) just unveiled an update. On January 30, 2026, Novocure Inc. disclosed that CMS had revoked its billing privileges for the company’s product...

People also own

Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.